Updated: 07/23/2014 6:14 PM
Created: 07/23/2014 6:13 PM WDIO.com
WASHINGTON (AP) - The Food and Drug Administration has approved a new combination pain pill from the maker of OxyContin that is designed to discourage abuse by painkiller addicts.
Purdue Pharma's new drug Targiniq ER is an extended release tablet that combines oxycodone - the active ingredient in OxyContin - with the drug naloxone. FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications.
If abusers crush the tablets for snorting or injecting naloxone blocks the euphoric effects of oxycodone, making the drug more difficult to abuse. Naloxone is currently used to reverse the overdose effects of opioids, highly addictive painkilling drugs including morphine, methadone, codeine and others.
The FDA notes that Targiniq can still be abused by simply swallowing the tablets, the most frequent method of painkiller abuse.
The FDA has been under intense public pressure to combat the national epidemic of prescription opioid abuse. Deaths linked to addictive medications like OxyContin and Vicodin have quadrupled since 1990 to an estimated 16,500 in 2010, the most recent year for which the Centers for Disease Control and Prevention reports figures.
Doctors prescribe opioids for a wide range of ailments, from post-surgical pain to arthritis and migraines.
Stamford, Connecticut-based Purdue has often been cited by public health advocates as a key contributor to the overprescribing of opioids. In 2007, Purdue Pharma and three of its executives paid $634 million and pleaded guilty to charges of misleading the public about the safety and addictiveness of OxyContin.
Since then the company introduced a harder-to-abuse version of OxyContin that is designed to resist crushing, chewing and dissolving.
"The FDA is committed to combatting the misuse and abuse of all opioids, and the development of opioids that are harder to abuse is needed in order to help address the public health crisis of prescription drug abuse in the U.S.," said FDA's Dr. Sharon Hertz.
The FDA is requiring Purdue to conduct long-term follow-up studies tracking rates of abuse, addiction, overdose and death with Targiniq. Those requirements are standard for all extended release opioid drugs approved in the U.S.
(Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Rural School Officials: Walker's Proposed Aid Won't Cut It
Gov. Scott Walker is prepared to spend millions more on rural schools, but some education officials say it won't be enough for some struggling districts.
Wisc. Republican Lawmaker Brings Back GPS Tracking Bill
A Republican lawmaker has reintroduced a bill that would outlaw using GPS to secretly track someone. Under Rep. Adam Neylon's bill, anyone who secretly placing a GPS device on another person's vehicle would be guilty of a misdemeanor punishable by up to nine months in jail and $10,000 in fines.
MNsure Open Enrollment Deadline Nears, Officials Urge Signups
The clock is winding down on MNsure open enrollment, with just three weeks left until a Feb. 15 deadline to sign up for health insurance through the exchange, so community leaders are using the time left to help people get enrolled...
Health Department Continues Survey on Medical Marijuana
Potential users of medical marijuana have about one week to participate in a survey that could help the state get a picture of the likely demand for the drug.
Students Help Hungry Youth Through 'We-CAN-Du' Fundraiser
Local DECA students are lending a hand to hungry youth as part of a "We-CAN-Du" fundraiser with a competitive spirit.